Drugs / CDX-622
last change Jun 2026 re-read 3 minutes ago

CDX-622

Developed for
asthma
Investigated by
Celldex Therapeutics

Trials 2

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07330778 Jun 2026 → Mar 2027 expected asthma Celldex Therapeutics Recruiting No outcome recorded
Phase 1 NCT06650761 Nov 2024 → Apr 2026 — Celldex Therapeutics Completed No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-06-14 Celldex Therapeutics Results Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting celldex.com ↗
Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels.
2025-10-30 Celldex Therapeutics Results Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition celldex.com ↗
CDX-622 was well tolerated, exhibited a good pharmacokinetic profile and induced rapid and sustained reductions in serum tryptase, indicative of mast cell inhibition and depletion.
2023-05-15 Celldex Therapeutics Results Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™ celldex.com ↗
The preclinical data show CDX-622 potently neutralizes the alarmin TSLP, a potent mediator of inflammation, and blocks SCF/KIT interaction required for mast cell function and survival.

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CDX-622 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650761 ↗
1

NCT07330778 ↗

Route Intravenous “IV single ascending doses (Part 1)” NCT06650761 ↗